FH Europe welcomes new Trustees
FH Europe is pleased to share the appointment of two new members to the Board of Trustees.
Please join us in welcoming Annelies Dol from the Netherlands and Gergely Jambrik from Hungary who were appointed to the Board on 16th February 2022. The new Trustees bring to FH Europe invaluable experience as individuals and family members directly affected by FH and Lp(a). Furthermore, as active members of patients’ organizations in their respective countries they combine a unique perspective and as incredibly accomplished professionals they also enhance the existing know-how available to the Board with different forms of legal expertise.
“I am very honoured to join FH Europe. Apart from my duty as Trustee, my purpose of being part of this organization is to create more awareness about Lp(a) amongst both patients and physicians. I hope that through our advocacy work – testing for LP(a) will be organized on a much broader and a more regular basis. I aim for every “CVD patient” that does not fall under the criteria of the traditional risk factors to be automatically tested for Lp(a) levels.” – Annelies Dol, FH Europe’s new Trustee and a Team member of ‘VrouwenHart’ (Women’s Heart), a Dutch patient organisation.
Gergely Jambrik, Co-Chair of the Heartily Hungary – a Hungarian patient organization, about becoming a Trustee with FH Europe “As an FH patient with an ‘adventurous’ history of diagnosis, I can say that joining Heartily Hungary and FH Europe in fact changed my life and how I and my family deal with FH. Thus, no wonder that I became more and more interested and active in the local and the European FH patient organizations’ work. But this turned out to be an ever-growing purpose. Having to deal with my child’s FH diagnosis and meeting the above patient organizations at the same time made FH patient advocacy a true mission for me.”
John Reeve, Chair of FH Europe, says “I am absolutely delighted at these two important appointments which bring the patient perspective once more into the heart of our leadership team. It positions us to move FH Europe onto the next level of its development. The new Board of Trustees and our Network of organisations, working together, will be a formidable force to reduce the impact of these insidious conditions. I am excited about the new chapter in FH Europe’s book that we will write with the contribution of our new ‘Patient Trustees’.”
“I look forward to our collaboration with the expanded Board, ensuring that our work both addresses the urgent public health priority and offers tangible solutions to save and serve even better the international community of people living with inherited, genetic dyslipidaemias (FH, HoFH, LP(a) and FCS).” adds Chief Executive of the organization, Magdalena Daccord.
As of today, FH Europe’s Board with eight Trustees and the Chief Executive represents 9 nationalities who among them speak English, French, German, Italian, Dutch, Romanian, Polish, and Hungarian. This diverse Board with a wide range of skills, experience and perspectives, bolsters the charity’s resilience and gives it the best chance of fulfilling its purposes into the future.
To meet Annelies, Gergely and other Trustees of the Board visit the FH Europe Trustees page
FH Europe is supported by an educational grant from Amgen Limited, Sanofi, Regeneron, Akcea Therapeutics Inc. and Amryt